Hybrid SA RGP Center/S-H Skirt Daily Wear 90 Day Multicenter Study
NCT ID: NCT00804505
Last Updated: 2009-12-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
98 participants
INTERVENTIONAL
2008-06-30
2008-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
* within the corresponding range of lens powers
* in a population randomized within multiple investigational sites
* with a study ration of 2/1 test vs control lenses
* for a duration of 90 days.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The purpose of the study is to demonstrate that the SynergEyes SA Hybrid Contact Lens clinical performance is substantially equivalent to that of the SynergEyes A Hybrid Lens when studied within the corresponding range of powers in a population randomized within investigational sites to produce a 2/1 ratio of Test vs. Control lenses.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Test arm daily wear hybrid contact lens.
SynergEyes Hybrid (petrafocon A hem-larafilcon A) Hybrid Contact Lens
Comparison to control hybrid lens with similar 'dose'minimum 8 hours daily use for up to 90 days.
2
Control: SynergEyes Hybrid (paflufocon D hem-iberfilcon A) Hybrid Contact Lens
SynergEyes Hybrid (paflufocon D hem-iberfilcon A) Contact Lens
Comparison to test lens: Daily use for minimum 8 hours up to 90 days.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
SynergEyes Hybrid (petrafocon A hem-larafilcon A) Hybrid Contact Lens
Comparison to control hybrid lens with similar 'dose'minimum 8 hours daily use for up to 90 days.
SynergEyes Hybrid (paflufocon D hem-iberfilcon A) Contact Lens
Comparison to test lens: Daily use for minimum 8 hours up to 90 days.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Be at least 18 years of age as of the date of evaluation.
2. Have
1. read the Informed Consent,
2. been given an explanation of the Informed Consent,
3. indicated an understanding of the Informed Consent and
4. signed the Informed Consent Form.
3. Be willing and able to adhere to the instructions set forth in this protocol and able to keep all specified appointments.
4. Be a current contact lens wearer.
5. Possess wearable and visually functional eyeglasses.
6. Be in good general health, based on his/her knowledge.
7. Require spectacle lens powers between plano and -6.00 diopters sphere with no more than -2.50 diopters of spectacle refractive astigmatism and be willing to wear lenses in both eyes.
8. Have manifest refraction visual acuity equal to or better than 20/25 in each eye.
TO BE ELIGIBLE FOR LENS DISPENSING, THE SUBJECT'S STUDY DEVICE CONTACT LENS VISUAL ACUITY MUST BE EQUAL TO OR BETTER THAN 20/30 IN EACH EYE
Exclusion Criteria
1. Subject is wearing lenses in a monovision modality and is unwilling to be fit with distance lenses in both eyes. NOTE: Subjects may NOT wear monovision lenses at any time during the study as it will interfere with the distance visual acuity measurement.
2. Subject exhibits poor personal hygiene.
3. Subject is currently or within 30 days prior to this study has been an active participant in another clinical study.
4. Subject is currently pregnant (to the best of the subject's knowledge), is planning a pregnancy within the next 3 months or is lactating.
5. Subject is a member, relative or household member of the office staff, including the investigator(s).
6. Subject has a known sensitivity to ingredients used in contact lens care products or over-the-counter lubricants and artificial tears.
7. Subject has undergone refractive surgery or is currently receiving or has previously received orthokeratology treatment.
8. Subject is aphakic or pseudophakic.
9. Subject has ocular or systemic disease such as, but not limited to: anterior uveitis or iritis (past or present), glaucoma, Sjögren's syndrome lupus erythematosus, scleroderma, keratoconus or type II diabetes.
10. Use of ocular medications for any reason or systemic medications which might interfere with contact lens wear.
11. A known history of corneal hypoesthesia (reduced corneal sensitivity).
12. Slit lamp findings that would contraindicate contact lens wear, including but not limited to:
* History of corneal ulcer, corneal infiltrates or fungal infections
* Corneal scars within the visual axis
* Pterygium
* Dry eye symptoms with decrease tear levels and punctate staining ≥ Grade 2
* Neovascularization or ghost vessels \> 1.5 mm in from the limbus
* Seborrhoeic eczema, seborrhoeic conjunctivitis
* History of papillary conjunctivitis that has interfered with lens wear or a current condition of Grade 2 (Mild) or greater
13. Clinically significant (Grade 3 or 4) anterior segment abnormalities or any infection of the eye, lids, or associated structures.
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
SynergEyes, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Joe Collins
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
William Gleason, OD
Role: STUDY_DIRECTOR
Foresight Regulatory Strategies, Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Carmel Mountain Vision Care
San Diego, California, United States
Silicon Valley Eye Physicians
Sunnyvale, California, United States
Casazza Optometric Group
Andover, Massachusetts, United States
Vision Care Associates
East Lansing, Michigan, United States
Western Reserve Vision Care, Inc.
Beachwood, Ohio, United States
Dr. Karambelas & Associates
Providence, Rhode Island, United States
Primary Eyecare Group P.C.
Brentwood, Tennessee, United States
Snowy Range Vision Center
Laramie, Wyoming, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SI-0804 V1.0
Identifier Type: -
Identifier Source: org_study_id